




MARCH 2020

CORPORATE PRESENTATION

CYDY : OTCQB



The pursuit of precision medicine



Forward looking information and statements

This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.

The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission.

Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this presentation.

Robust Pipeline

Mechanism of Action: Leronlimab as a CCR5 antagonist

PROGRAM	INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
HIV	NIH - <2010 RR-2019 Combination Therapy ¹ FTD-2006	██████████	██████████	██████████	██████████
	Monotherapy ²	██████████	██████████	██████████	██████████
Cancer	Triple-Negative Breast ⁵ FTD-2019	██████████	██████████	██████████	██████████
	Basket trial for 22 solid tumors (including melanoma, brain-glioblastoma, throat, lung, stomach, colon, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications)	██████████	██████████	██████████	██████████
Immunology	GvHD ³ ODD-2017	██████████	██████████	██████████	██████████
	NASH ⁴	██████████	██████████	██████████	██████████
	Coronavirus [COVID-19] ⁶	██████████	██████████	██████████	██████████
	Autoimmune (mutple potential indications including Crohn's disease, IBS (inflammatory bowel syndrome), MS (Multiple Sclerosis), Hashimoto's thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Grave's disease, Sjogren's syndrome, Myasthenia gravis)	██████████	██████████	██████████	██████████

¹ BLA filing in-process, 1/3rd complete

² Protocol for pivotal Phase 3 trial filed

³ Trial underway with Orphan Drug designation

⁴ IND and Phase 2 protocol filed

⁵ Trial underway with Fast Track designation

⁶ Patient treatment underway via Emergency IND; Phase 2 trial protocol filed


The Science Behind Leronlimab

The Next Generation of Monoclonal Antibody Therapy

CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications.

How it Works


The target of leronlimab (PRO 140) is the important immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of a variety of cells including white blood cells and cancer cells. On white blood cells, it serves as a receptor for chemical attractants called chemokines. The CCR5 receptor is also the coreceptor needed for HIV to infect healthy T-cells. Recent research has identified the CCR5 receptor as an important target for many disease processes including cancer metastasis and certain immunological conditions.



HIV Combination Therapy – Status of Clinical Trials and BLA

leronlimab in combination with HAART

(highly active antiretroviral therapy)




- ✓ Leronlimab has received Fast-Track Designation, and “accelerated approval is possible” (FDA)
- ✓ Phase 3 pivotal trial completed and hit primary end point $p=0.0032$
- ✓ 24 weeks of safety data. 81% of patients w/ suppressed viral load compared to 43% (per last approved drug for this pop.)
- ✓ No reported drug-related Serious Adverse Events (SAE’s) – high safety profile for leronlimab
- ✓ BLA submission granted “rolling review” (FDA) – final two portions to be submitted in April 2020

Label submission to be requested:

- One drug resistance in 3 classes; or
- One drug resistance in 2 classes with limited treatment options to another class

HIV Combination Therapy – Leronlimab and HAART



HIV Monotherapy Status


Currently in Phase 2/3 Investigative Trial

- **Objective of trial**: Assess the subcutaneous use of leronlimab as a long-acting single agent maintenance therapy for 48 weeks in patients with suppressed viral load with CCR5-tropic HIV-1 infection
- **Primary Endpoint**: Proportion of participants with a suppressed viral load to those who experienced VF
- **Secondary Endpoint**: Length of time to VF

STATUS

- Enrollment closed after reaching 565 patients
- Trial also being used to provide safety data for BLA filing for leronlimab as a combination therapy
- Higher responder rate prompted us to file a Phase 3 pivotal trial protocol with the FDA for leronlimab monotherapy as switch therapy
- In discussion with FDA to finalize protocol, after which we expect to initiate the Phase 3 trial

215 patients approached 1 year & 5 patients have surpassed 5 years







Commercial Partnership - Large scale biologics manufacturing capacity for leronlimab

The Samsung Biologics logo, with "SAMSUNG" in blue and "BIOLOGICS" in black, set against a background of a laboratory or factory interior.

- Deal signed April 2019
- Build-out in process
- Targeted minimum capacity commitment will be reached by end of 2020, with additional capacity as needed. First delivery of clinical grade leronlimab is targeted for Q2-2020



Commercialization Plan - Leronlimab


Activity	Estimated Timeline										Goal	Impact		
	2019		2020				2021							
	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
BLA Approval												Branding / labeling / marketing	Support Commercialization	
Commercial Readiness														
Labeling / Marketing												Strong product launch	Product awareness / applicability	
Manufacturing														
 AGC Biologics												Existing biologics manufacturer	Product availability upon FDA approval	
 SAMSUNG BIOLOGICS												Technical transfer, commence mfg	Prepare for lower cost, ensure stability	
Commercialization												Revenue Stream	Cash Flow	
Mfg & Cost Efficiency														
 SAMSUNG BIOLOGICS												Post-transfer mfg ramp-up	Volume-based margin improvement	
Commercial Stabilization												Balance multiple sources of supply	Optimize supply chain and cost	
700 mg Dose to 525 mg Dose												TBD ()	Dosage optimization	Eliminate waste / improve cost profile
Vials to PFS "Pre-filled Syringe"													Improved patient delivery	Cost improvement. ETA ~ 2022

The Evolving Power of Ieronlimab

Cancer

Immunology


Leronlimab targets an important G protein coupled receptor - CCR5. CCR5 is more than just a pathway to HIV replication, but also a key mediator in many cancer metastasis and a crucial component of inflammatory responses



Cancer Pipeline and Status

mTNBC

- Phase 1b/2 initiated – unmet medical need
- Granted Fast-Track designation by FDA based on a greater than 98% reduction of metastatic tumor volume in a murine xenograft model
- March 2020 - **Twelve patients injected**
- Based on current results, CytoDyn will ask for BTD preliminary meeting



Colon Cancer

- Green light from FDA to initiate Phase 2 trial

More than 20 potential **CANCER** indications

Esophagus, Squamous head & neck, Melanoma, Brain-glioblastoma, Throat, Lung including non small cell, Stomach, Colon carcinoma, Breast, Testicular, Ovarian, Uterine, Pancreas, Bladder, Thyroid, Other endocrine, Blood/bone marrow CLL, AML, Hodgkin's and non-Hodgkin's lymphoma, other liquid/blood tumors, Sarcomas

More than 10 potential indications in **AUTOIMMUNE DISEASES**


Crohn's disease, IBS (inflammatory bowel syndrome), MS (Multiple Sclerosis), Hashimoto's thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune hepatitis, Graves' disease, Sjogren's syndrome, Myasthenia gravis

Immunology Pipeline and Status


GvHD (Graft vs. Host Disease)

- FDA granted Orphan Drug Designation (ODD)
- Xeno-GvHD Human BM transplanted into Immuno-Deficient mice

*Study was published in peer-reviewed publication:
"Biology of Blood and Marrow Transplantation"*



- Phase 2 trial initiated
- Amended protocol for Phase 2 trial received IRB approval
- Patient enrollment underway at five clinical sites




NASH (non-alcoholic steatohepatitis)

- Received clearance from FDA to initiate enrollment in a Phase 2 clinical trial
- Trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH
- Phase 2 trial is a 60-patient, multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of leronlimab in adult patients with NASH

AUTOIMMUNE - Pre-clinical data on over 10 multiple potential indications including:

Crohn's disease, IBS (inflammatory bowel syndrome), MS (Multiple Sclerosis), Hashimoto's thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Grave's disease, Sjogren's syndrome, Myasthenia gravis)

Forward-facing Strategy



Out-licensing Opportunities

- As our portfolio matures, consideration of licensing deals with upfront payments, milestone payments and revenue-share

Strategic Partnerships

- Exploring expressions of interest for direct investment and co-development arrangements with large bio-pharma
- Exploring avenues for synergistic mergers

Ongoing R&D in Oncology & Immunology

- Advance indications in Oncology and Immunology

Patents

- Existing comprehensive footprint for multiple indications, in multiple countries
- Industry-leading legal and regulatory resources committed to further buildout of patent footprint

Management Team and Board of Directors

Executive Management Team



Dr. Nader Z. Pourhassan, Ph.D.
President, CEO and Director

10 years at CytoDyn, driving the development of leronlimab. Exceptional background in Mechanical Engineering, Business Development and Operations.



Craig S. Eastwood, CPA
Chief Financial Officer

More than 25 years of experience in senior and executive finance roles at public and private companies, including over 3 years at a global Contract Research Organization.



Dr. Nitya G. Ray, Ph.D.
Chief Technology Officer, Head of Process Sciences, Mfg & Supply Chain

Over 30 years experience in biologics manufacturing, including engineered tissue therapeutics, antibody drug conjugates, and small molecule drugs.



Dr. Brendan Rae, Ph.D. J.D.
Senior Vice President of Business Development

Accomplished licensing and business development executive - large Bio-Tech companies. Experience as an attorney focused on biopharma intellectual property law.


Board of Directors



Dr. Scott A. Kelly, M.D.
Chairman of the Board



Dr. David F. Welch, Ph.D.
Director



Jordan G. Naydenov
Director



Alan P. Timmins
Director

Our Priority and Passion:

1ST

Saving human lives

2nd

Improving quality of life

Increasing shareholder value will make these two possible